← Back to Search

Depo-Medrol for Postoperative Pain

Phase 4
Recruiting
Led By Hardeep Singh, M.D.
Research Sponsored by Hardeep Singh
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients with lumbar disc degeneration
Transpsoas (PTP or LTP) lateral lumbar interbody fusion (LLIF) 1-3 disc levels with posterior instrumentation (Open or MIS) with or without laminectomy, must include L3-4 and/or L4-5
Must not have
Spondylolisthesis >Grade 1
Patients requiring bilateral transpsoas approaches
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year and 2 years
Awards & highlights
Drug Has Already Been Approved
Pivotal Trial

Summary

This trial is testing whether an injection of a steroid called Depo-medrol can help reduce hip and thigh pain after a specific type of back surgery. The goal is to see if this injection can make recovery easier for patients by reducing pain and weakness in the hip area. Depo-medrol, a corticosteroid, has been used in various medical contexts to reduce pain and inflammation, including postoperative settings.

Who is the study for?
This trial is for adults aged 18-75 with lumbar disc degeneration who are undergoing a specific back surgery (LLIF) involving the L3-4 and/or L4-5 spinal levels. Candidates must not have severe spine curvature, advanced spondylolisthesis, flatback deformity, diabetes requiring insulin, or be chronic oral steroid users. They also can't have allergies to steroids like Depo-Medrol.
What is being tested?
The study tests whether injecting Depo-Medrol into the psoas muscle after LLIF surgery reduces postoperative hip flexor weakness and thigh pain/numbness. It compares this treatment against Gel-Flow NT to see which is more effective in managing these symptoms.
What are the potential side effects?
Depo-Medrol may cause side effects such as increased blood sugar levels, weakened bones, weight gain, water retention, mood swings or changes in behavior. The severity of side effects varies from person to person.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have degeneration in my lumbar disc.
Select...
I had a specific spine surgery involving L3-4 and/or L4-5 levels.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My spine condition is more severe than a mild slip.
Select...
I need surgery on both sides of my spine through the psoas muscle.
Select...
I am unable to give consent by myself.
Select...
I have pain in the same side of my hip.
Select...
I am scheduled for or have had a revision fusion surgery.
Select...
I have a flatback deformity.
Select...
I have a curve in my spine greater than 10 degrees.
Select...
I regularly take oral steroids.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year and 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Quantify the difference in thigh pain measured on the visual analog pain scale (VAS) between those receiving a depo-medrol injection and those who did not over 3 postoperative time periods: 2-3, 6, and 12 weeks following surgery.
Secondary study objectives
Determine effect of depo-medrol application on fusion rates and how it differs between those that did and did not receive a depo-medrol injection.
Quantify the difference in rates of postoperative thigh numbness both with and with out application of depo-medrol to the psoas between those that did and did not receive a depo-medrol injection.
Quantify the difference in severity of postoperative hip flexor weakness both with and with out application of depo-medrol to the psoas between those that did and did not receive a depo-medrol injection.
+3 more

Awards & Highlights

Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Test group (standard care + study intervention)Experimental Treatment2 Interventions
1 cc of gel foam powder mixed with thrombin and 80mg Depo-Medrol
Group II: Control group (standard care)Placebo Group1 Intervention
1 cc gel foam powder mixed with thrombin
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Depo-Medrol
2005
N/A
~260

Find a Location

Who is running the clinical trial?

Society for Minimally Invasive Spine SurgeryOTHER
1 Previous Clinical Trials
450 Total Patients Enrolled
Hardeep SinghLead Sponsor
Hardeep Singh, M.D.Principal InvestigatorUConn Health

Media Library

Test group (standard care + study intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05929755 — Phase 4
Muscular Weakness Research Study Groups: Test group (standard care + study intervention), Control group (standard care)
Muscular Weakness Clinical Trial 2023: Test group (standard care + study intervention) Highlights & Side Effects. Trial Name: NCT05929755 — Phase 4
Test group (standard care + study intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05929755 — Phase 4
~25 spots leftby Aug 2025